Allergan PLC. (AGN) Position Lowered by Daiwa SB Investments Ltd.
Daiwa SB Investments Ltd. reduced its position in shares of Allergan PLC. (NYSE:AGN) by 4.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 15,590 shares of the company’s stock after selling 650 shares during the period. Allergan PLC. comprises 1.0% of Daiwa SB Investments Ltd.’s investment portfolio, making the stock its 28th largest position. Daiwa SB Investments Ltd.’s holdings in Allergan PLC. were worth $3,790,000 as of its most recent SEC filing.
Several other hedge funds have also bought and sold shares of AGN. GWM Advisors LLC raised its position in shares of Allergan PLC. by 0.4% in the first quarter. GWM Advisors LLC now owns 1,260 shares of the company’s stock valued at $300,000 after buying an additional 5 shares during the period. Burns J W & Co. Inc. NY raised its position in shares of Allergan PLC. by 0.7% in the second quarter. Burns J W & Co. Inc. NY now owns 906 shares of the company’s stock valued at $220,000 after buying an additional 6 shares during the period. Trust Co raised its position in shares of Allergan PLC. by 0.8% in the first quarter. Trust Co now owns 1,224 shares of the company’s stock valued at $292,000 after buying an additional 10 shares during the period. JNBA Financial Advisors raised its position in shares of Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock valued at $116,000 after buying an additional 12 shares during the period. Finally, Tarbox Group Inc. raised its position in shares of Allergan PLC. by 0.6% in the first quarter. Tarbox Group Inc. now owns 2,393 shares of the company’s stock valued at $572,000 after buying an additional 15 shares during the period. Institutional investors and hedge funds own 83.63% of the company’s stock.
Shares of Allergan PLC. (AGN) traded down 0.47% during trading on Wednesday, reaching $229.36. The company’s stock had a trading volume of 1,688,271 shares. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80. The stock has a market capitalization of $76.68 billion, a price-to-earnings ratio of 6.99 and a beta of 1.16. The company’s 50-day moving average price is $245.03 and its 200 day moving average price is $238.77.
Allergan PLC. (NYSE:AGN) last posted its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The firm had revenue of $4.01 billion during the quarter, compared to analyst estimates of $3.95 billion. During the same quarter in the prior year, the business posted $3.35 earnings per share. The company’s quarterly revenue was up 8.8% compared to the same quarter last year. Analysts anticipate that Allergan PLC. will post $16.27 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be given a $0.70 dividend. This represents a $2.80 annualized dividend and a yield of 1.21%. The ex-dividend date of this dividend is Wednesday, August 16th. Allergan PLC.’s dividend payout ratio (DPR) is presently 9.95%.
WARNING: This article was originally published by Daily Political and is owned by of Daily Political. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/08/16/allergan-plc-agn-position-lowered-by-daiwa-sb-investments-ltd-2.html.
Several research firms recently issued reports on AGN. UBS AG reiterated a “buy” rating and issued a $275.00 price objective on shares of Allergan PLC. in a report on Monday, May 15th. Vetr upgraded Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 price target on the stock in a report on Monday, June 26th. Royal Bank Of Canada set a $284.00 price target on Allergan PLC. and gave the stock a “buy” rating in a report on Monday, June 12th. BidaskClub upgraded Allergan PLC. from a “hold” rating to a “buy” rating in a report on Saturday, June 24th. Finally, Mizuho restated a “buy” rating and set a $267.00 price target on shares of Allergan PLC. in a report on Wednesday, August 2nd. Eight analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $275.49.
In other news, Director Nesli Basgoz sold 1,889 shares of the firm’s stock in a transaction that occurred on Thursday, May 18th. The shares were sold at an average price of $220.45, for a total transaction of $416,430.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.36% of the company’s stock.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.